Inotek Pharmaceuticals Corp., of Lexington, Mass., completed the first two of three stages of a multiple-dose Phase IIb trial of its eye drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of the milestone, Inotek's investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase.